Dianthus Therapeutics, INC /DE/ 10-Q quarterly reports

Dianthus Therapeutics reports significant cash increase following a large public offering, advances clinical trials for claseprubart and DNTH212, and maintains sufficient funding into 2030.

Dianthus Therapeutics announces positive Phase 2 data for claseprubart in gMG, licenses new bifunctional inhibitor DNTH212, and secures $288.4 million in public offering proceeds, extending cash runway into 2028.

Dianthus Therapeutics reported a significant increase in net loss and R&D expenses for the first half of 2025, driven by advancing clinical trials for its lead candidate, claseprubart, while maintaining a cash runway into late 2027.

Dianthus Therapeutics reports its financial results for the first quarter of 2025, highlighting progress in its clinical trials and providing an update on its financial position.

Dianthus Therapeutics reported a net loss of $25.2 million for the third quarter of 2024, alongside updates on clinical trials and financial activities.

Dianthus Therapeutics, a clinical-stage biotechnology company, released its second quarter 2024 financial results, highlighting progress in its clinical programs and financial position.

Dianthus Therapeutics reported a net loss of $13.7 million for the first quarter of 2024, alongside a significant increase in cash reserves following a private placement.